Table 2 Association of ECR with one-year disease progression and development of ESRD.

From: Urinary endotrophin predicts disease progression in patients with chronic kidney disease

Model

One-year disease progression

ESRD

ORa (95% CI)

P-value

HRa (95% CI)

P-value

Model a

1.55 (1.20–2.02)

0.0009

1.15 (1.00–1.31)

0.04

Model b

1.80 (1.37–2.35)

<0.0001

1.30 (1.16–1.00)

<0.0001

Model c

1.42 (1.04–1.93)

0.03

0.95 (0.81–1.11)

0.51

Model d

1.63 (1.15–2.32)

0.007

0.98 (0.83–1.16)

0.82

  1. Data are odds ratio (OR) or hazard ratio (HR) with 95% CI as specified. One-year disease progression was defined as either a decline of eGFR of more than 30% or development of ESRD within one year. Urinary ECR was adjusted in four different models: Model a) ECR adjusted for eGFR; Model b) ECR adjusted for ACR; Model c) ECR adjusted for eGFR and ACR; and Model d) ECR adjusted for all variables with a univariable association with ECR (p < 0.1) and gender16. The variables included in the latter model (“Model d”) included age, gender, ethnicity, primary renal diagnosis, diabetes mellitus as comorbidity, age-adjusted CCI (score ≥ 5), PP, eGFR, and ACR. Due to missing data for some variables used for adjustment, the fully adjusted model only included 406 out of 416 patients (98%) with data available for one-year disease progression and 484 out of 499 patients (97%) for development of ESRD. Logistic regression analysis was used to analyze the association to one-year disease progression, and Cox proportional hazard regression analysis was used to analyze the association to development of ESRD. ECR, endotrophin:creatinine ratio; CCI, Charlson’s comorbidity index; PP, pulse pressure; eGFR, estimated glomerular filtration rate; ACR, albumin creatinine ratio. aper increase in one standard deviation (1 SD) of ECR.
Back to article page